News Features Once Burned, Twice Shy, Cardiologists Ditch X for Bluesky Yael L. Maxwell November 29, 2024
News Features A Sham-Controlled Trial of AF Ablation Is Feasible, but Is It Needed? Todd Neale January 25, 2024
News Features Skyrocketing Popularity Puts GLP-1 Agonists for Weight Loss on Cardiology’s Radar L.A. McKeown May 12, 2023
News Features Prudence or Spin? Mulling Embolic Protection After PROTECTED TAVR Todd Neale October 17, 2022
News Features Novel Targets, Gene Edits, and Vaccines: Is a ‘Golden Era’ Dawning for ASCVD? Michael O'Riordan August 15, 2022
News Features Pricey Inclisiran Is Rolling Out: a ‘Buy-and-Bill’ Model May Smooth Its Path Michael O'Riordan January 17, 2022
News Features Four Pillars, Fast? Rapid Sequencing of HF Drugs Faces an Uphill Battle Shelley Wood October 08, 2021
News Features When the Time Comes to Stop Oral Anticoagulation: Options and Obstacles Todd Neale September 28, 2021
News Features Hydroxychloroquine: No Help, Clear Harm in COVID-19 RCT and Cohort Studies Shelley Wood May 20, 2020
News Features Hospitals Plan Cautious Restart to Elective Procedures as COVID-19 Wanes Michael O'Riordan May 12, 2020
News Features Obesity and COVID-19: Theories and Blame Fill the Scientific Void Shelley Wood April 21, 2020
News Features ‘Salvage What We Can’: Cardiology Clinical Trials in Turmoil Amid COVID-19 Michael O'Riordan April 07, 2020
News Features EXCEL Investigators Respond to Data Suppression Claims as Debate Erupts Online Michael O'Riordan December 12, 2019
News Features Year in Review: SGLT2 Inhibition, Lipid-Lowering Make Waves in Clinical Cardiology in 2019 Todd Neale December 10, 2019
News Features Wearables Under the Microscope: How New Tech Will Disrupt Patient-Physician Dynamics Marcus A. Banks August 15, 2019
News Features Anticoagulation On Demand? The Pill-in-the-Pocket Approach to A-fib Treatment Todd Neale June 25, 2019
News Features Hopes Fade for a CV Indication for Canakinumab: What’s Next for the Inflammatory Hypothesis? Michael O'Riordan February 01, 2019